Gilead Sciences News

Brazil's National Institute of Industrial Property has rejected a patent on Gilead's version of tenofovir, one of the most commonly used antiretroviral drugs, following a lengthy investigation.

Brazil's government has turned down a patent application from US drugmaker Gilead Sciences for its HIV/AIDS drug Viread , after the country's patent office ruled that it lacked technological inventiveness.

Google to release its Internet browser today Verne Kopytoff, Chronicle Staff Writer Google Inc.

The biopharmaceutical company plans to add about 1,900 jobs and double office and lab facilities at its Foster City, Calif., headquarters over the next 10 years.

Patrick O'Brien, Investor Relations, 650-522-1936 Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Thomas Weisel Partners Healthcare Conference in Boston.

Biotechs often take years before producing a profit, as they're often in the development stages of drugs.

Gilead Sciences Inc. plans to nearly double the office and R&D space at its Foster City headquarters as it adds 1,900 jobs there over 10 years.

Produced by the Foster City-based Gilead Sciences, the once-daily tablet Viread has been granted marketing approval for the treatment of chronic hepatitis B by the U.S. Food and Drug Administration, the ...

Overshadowed by gyrations in the credit, commodity, and energy markets, biotech has been a sleeper with positive returns.

Gilead Sciences this week announced that the U.S. Food and Drug Administration has approved tenofovir for the treatment of chronic hepatitis B virus infection .

Gilead Sciences said on Monday it won U.S. approval to promote its AIDS drug Viread for treating adults with chronic hepatitis B. Hepatitis B is a potentially life-threatening infection that can destroy the ...

Investors were high on health stocks Friday, reestablishing gains for the week's close.

Dr. Richard J. Whitley, a UAB pediatrics, microbiology, medicine and neurosurgery professor, has been named a director for Gilead Sciences Inc ., the Foster City, Calif.-based biopharmaceutical company said ...

Drugs made by Gilead Sciences Inc . that have been shown to treat the AIDS virus will be tested in healthy people to see if they can prevent the lethal disease.

Data presented at an international HIV conference this month could boost sales of Gilead Sciences Inc.

The granddaddy of monthly economic reports is the federal reading on the employment situation.

Gilead Sciences Ltd. and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla in Twelve Countries 8/1/2008 FOSTER CITY, Calif.

Today's interview is with senior analyst Jason Napodano, who discusses Genentech , Biogen Idec , Gilead , Celgene and Pfizer .

When Eugene Sit founded his Sit Mid Cap Growth fund nearly 27 years ago, he insisted it follow two principles: integrity and above-average, sustainable growth.

A Korean state research institute said yesterday it has sold technology for producing an effective anti-AIDS material to a leading pharmaceutical company in the United States.